ASX: HCT’s Path‐Away® Tests Successful Against SARS-CoV-2

One of the primary US certified environmental testing services, Holista Colltech Limited (ASX:HCT) has completed testing its Path-Away® against the virus SARS-CoV-2 that triggers Covid-19. The research was carried out by Microbac Laboratories, Inc.

Path-Away® attained a 3-Log reduction, about 99.9% of the virus within the span of two minutes, on a hard surface. Log reduction stands for a 10-fold or 90% reduction in numbers of live bacteria. Therefore, a 3-Log reduction suggests 99.9% decline in the likely harmful microorganisms.

Meanwhile, Path-Away® as an anti-pathogenic aerosol solution, was successfully tested on the substitute of SARS-CoV-2 in April 2020.

According to the GICC-LLC, Global Infection Control Consultants, this is expected to be the world’s first completely natural and organic disinfectant, meeting the USA assessment guidelines.

Path-Away® is the active component in sanitizers NatShield™ and Protectene™, both formulated by Holista.

HCT share price quoted at $0.130 at AEDT 01:50 PM on 20 October 2020.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and